Paper Details

  1. Home
  2. Paper Details

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

Author: , BakerDaniel, BathonJoan M, DewoodyKimberly, EmeryPaul, KaldenJoachim R, KeystoneEdward, MainiRavinder N, SchiffMichael, SmolenJosef S, St ClairE William, WangBen, WeissRoberta, van der HeijdeDésirée M F M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Combination therapy with methotrexate (MTX) and infliximab provides greater clinical, radiographic, and functional benefits than MTX alone for patients with active rheumatoid arthritis (RA) in its early stages. However, infliximab therapy is associated with a significantly higher incidence of serious infections, especially pneumonia.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To compare the benefits of initiating treatment with methotrexate (MTX) and infliximab (anti-tumor necrosis factor alpha [anti-TNFalpha] monoclonal antibody) with those of MTX treatment alone in patients with rheumatoid arthritis (RA) of < or =3 years' duration. METHODS: RA patients were...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/art.20568

データ提供：米国国立医学図書館（NLM）

Infliximab and Methotrexate: A Powerful Duo for Early Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic autoimmune disease that can cause significant joint pain, swelling, and stiffness. This study investigated the benefits of combining infliximab, an anti-tumor necrosis factor alpha (anti-TNFalpha) monoclonal antibody, with methotrexate (MTX) in patients with early RA. The researchers compared the efficacy and safety of this combination therapy with MTX alone in patients with RA of less than or equal to three years' duration.

The randomized controlled trial involved 1,049 patients who were randomly assigned to three treatment groups: MTX-placebo, MTX-3 mg/kg infliximab, and MTX-6 mg/kg infliximab. The study found that combination therapy with infliximab and MTX resulted in significantly greater clinical, radiographic, and functional benefits compared to MTX alone. However, the combination therapy was associated with a higher incidence of serious infections, particularly pneumonia.

Combination Therapy: A Promising New Approach for Early RA

The study's findings suggest that combination therapy with infliximab and MTX may offer a more effective treatment option for patients with early RA compared to MTX alone. However, the increased risk of serious infections, particularly pneumonia, warrants careful consideration and close monitoring of patients receiving combination therapy.

Living with Rheumatoid Arthritis: A Journey of Management

RA is a chronic condition, and finding the right treatment plan is crucial for managing symptoms and improving quality of life. This study highlights the potential benefits of combination therapy for early RA, but it is essential to discuss the risks and benefits of treatment options with your healthcare provider.

Dr.Camel's Conclusion

This research is like a desert expedition, exploring new pathways to manage RA. Combining infliximab and MTX is like finding a more effective and efficient route through the desert. While this combination offers advantages, it is important to be aware of the potential challenges, like the increased risk of infections. As always, navigating this complex disease requires careful consideration and expert guidance.

Date :
  1. Date Completed 2004-12-17
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

15529377

DOI: Digital Object Identifier

10.1002/art.20568

Related Literature

Article Analysis
・Effective treatment of rheumatoid arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.